Details for Patent: RE45128

« Back to Dashboard

Summary for Patent: RE45128

Title:	Cephalotaxane derivatives and their processes of preparation and purification
Abstract:	The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
Inventor(s):	Jean-Pierre Robin, Julie Blanchard, Jean-Pierre Marie, Nina Radosevic
Assignee:	Teva Pharmaceuticals International GmbH
Application Number:	US13/661,677
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent RE45128

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: RE45128

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	98 03492	Mar 20, 1998

International Family Members for US Patent RE45128

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	289312
Australia	2002304338
Australia	3270699
Canada	2324895
Canada	2441428